Ageing and remyelination failure in people with multiple sclerosis.

ABSTRACT: One of the most promising strategies to delay, prevent, or reverse disability progression in multiple sclerosis is enhancing endogenous remyelination. While preclinical research has established a strong connection between ageing and remyelination failure, evidence for this same link in people with multiple sclerosis remains less secure. As clinical trials for remyelinating therapies progress, clarifying this relationship is essential. A deeper understanding could guide the selection of therapeutic candidates, refine patient selection, and optimize the timing of treatment delivery. In this review, we describe the available evidence that has investigated the impact of age on remyelination in people with multiple sclerosis. We categorize these into pathological, imaging and clinical studies.

SUBMITTER: Mukherjee T 

PROVIDER: S-EPMC12782174 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature